Acellular Amnion Fluid for Joint Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, a degenerative joint disease, primarily focus on pain relief and do not address tissue regeneration or protection, leading to the need for total joint replacement surgery in severe cases, and this issue extends to other connective tissue diseases and conditions like chronic skin wounds.
Innovation Solution
A growth-factor and cytokine-rich fluid derived from human amnion cells, referred to as an acellular human amnion-derived fluid composition, is administered locally to induce tissue remodeling, cellular proliferation, angiogenesis, anti-inflammatory responses, and anti-microbial activity, providing a regenerative therapy for degenerative joint disease and other connective tissue conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If total joint replacement surgery is performed, then pain relief and functional restoration are achieved, but loss of natural joint function and invasive procedure risks occur
Solution Approach 1:
The patent extracts and utilizes growth factors and cytokines naturally present in amniotic fluid, isolating the regenerative components from the whole amniotic membrane to create a targeted therapy that addresses joint degradation without requiring surgical replacement
Solution Approach 2:
The composition acts as a biological intermediary by introducing exogenous growth factors and cytokines that mediate tissue repair and regeneration processes, bridging the gap between current degraded joint state and desired healthy state without mechanical replacement
2Ease of operation
If pharmaceutical pain relief is used, then pain symptoms are managed, but tissue regeneration and disease progression prevention do not occur
Solution Approach 1:
The patent changes the therapeutic parameter from simple pain symptom management to active tissue regeneration by introducing biological agents that stimulate cellular processes, transforming the treatment approach from palliative to curative
3Reliability
If regenerative therapy is developed, then tissue regeneration and protection are achieved, but treatment complexity and manufacturing challenges increase
Solution Approach 1:
The patent creates a universal composition containing multiple growth factors and cytokines that can treat various joint diseases and connective tissue conditions with a single product, reducing the need for multiple specialized treatments and simplifying the therapeutic approach
Data Source
AI summary
Methods of treating alopecia, connective tissue disease, or chronic skin wounds in a subject by administration of a therapeutically effective amount of a novel acellular human amnion-derived composition are disclosed. The novel acellular human amnion-derived composition is generally characterized as containing: one or more tissue-remodeling biomolecules, one or more proliferation biomolecules, one or more angiogenic biomolecules, one or more migration biomolecules, one or more anti-inflammatory biomolecules, and one or more anti-microbial biomolecules. Moreover, the acellular human amnion-derived composition is sterilized under conditions that preserve biological functionality and efficacy. Other features and characteristics of the treatment methods and compositions are described.